Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat.com Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorBy Jeffrey Neal Johnson. Date Posted: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces renewed volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of roughly $245 per share, creating a divergence that has caught Wall Street's attention. This rally contradicts the common perception of the healthcare giant as a slow-moving, boring stock. Over the past 30 days, shares have climbed about 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and strong operational execution. Fraud is being exposed everywhere right now. Billions gone.
But they're missing the big one...
A legal scam that affects 95% of ALL Americans.
Oxford Club's own Marc Lichtenfeld hit the streets of South Florida to expose it in broad daylight.
Watch along as he captures real people's reactions LIVE on camera. Click Here to Watch What Happens For investors watching the ticker today, Feb. 24, 2026, note that this is the ex-dividend date for Johnson & Johnson. The stock price will likely decline by the amount of the upcoming dividend payment—$1.30 per share—a mechanical market adjustment rather than a reflection of business performance. For income-focused investors, this technical dip often represents an attractive entry point rather than a signal to sell. 64 Years of Unbroken Growth The primary case for owning Johnson & Johnson during turbulent market cycles is its financial stability and its role as a portfolio stabilizer. The company is part of an elite group of equities known as Dividend Kings—companies that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has raised its dividend for 64 consecutive years, a record that spans multiple recessions, market crashes, and geopolitical conflicts. That kind of reliability is rare in a market fixated on speculative growth. JNJ currently yields approximately 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in the bond market or in riskier sectors, the appeal here is the combination of growth and safety. The dividend is supported by a substantial liquidity cushion: management projects free cash flow of roughly $21 billion in 2026. That level of cash generation helps ensure the company can continue paying shareholders, invest in research, and manage legal expenses without heavy borrowing. For risk-averse investors, the stock's beta may be the most compelling metric. Beta measures how much a stock moves compared with the overall market (S&P 500). A beta of 1.0 means a stock moves in lockstep with the market; Johnson & Johnson's beta is about 0.35, meaning it has historically been roughly 65% less volatile than the broader market. When tech shares swing wildly, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio acts as a mathematical shock absorber, dampening overall volatility while retaining equity exposure. Beyond the Patent Cliff: The Road to $100 Billion Contrary to the idea that "safe" stocks can't grow, Johnson & Johnson is demonstrating meaningful momentum with a strategic pivot. Management has issued strong guidance for 2026, projecting full-year revenue to cross the $100 billion threshold for the first time in company history. Alongside that milestone, the company anticipates adjusted earnings per share (EPS) of about $11.53. This growth is driven by a reinvention of its pharmaceutical division, now branded Innovative Medicine. Investors had been worried about the patent cliff around Stelara, a blockbuster immunology drug that lost exclusivity in 2025. Typically, top drugs facing generic competition see revenues decline sharply; J&J has offset that drop with the rise of new blockbusters. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse is generating about $14 billion in annual sales and has cemented J&J's leadership in multiple myeloma treatment.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently posted strong three-year remission data for ulcerative colitis—evidence that J&J can retain market share in the competitive immunology space.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech division, which has shifted focus toward high-growth, high-margin technologies. A notable example is the integration of Shockwave Medical to modernize the cardiovascular portfolio. Shockwave employs intravascular lithotripsy (IVL) technology, using sonic pressure waves to safely break up calcified plaque in arteries—similar to how kidney stones are treated. This represents a significant upgrade over traditional angioplasty balloons. Owning this technology gives Johnson & Johnson a high-growth asset that complements its cardiovascular and surgical businesses. J&J is also pushing into robotics. The submission of the Ottava robotic surgical system for FDA approval signals an intent to compete in the expanding soft-tissue robotics market. These high-tech devices carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind that goes beyond selling consumables or basic surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is actively reshaping the corporate structure. A major development is the potential separation of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a mega sale of the asset. Divesting the orthopedics unit is a classic addition-by-subtraction move. Orthopedics is a mature, lower-growth business compared with booming fields like oncology and cardiovascular devices. Shedding this slower unit would improve overall revenue growth and profit margins. A sale could also generate a significant lump-sum cash infusion—potentially billions of dollars—providing capital for acquisitions or share buybacks. No balanced analysis of Johnson & Johnson is complete without addressing legal risks. The company continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in the headlines. A commercial lawsuit from Bayer regarding marketing claims for prostate cancer drugs has added further noise. Still, the stock's recent rally suggests the market is looking past these headlines. The prevailing view among bulls is that Johnson & Johnson has the financial depth to manage these liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company has a financial cushion capable of absorbing legal settlements. That strength helps ensure legal battles remain a balance-sheet item rather than an existential threat to the dividend or to operations. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. By shedding its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, the company is streamlining to focus on higher-growth opportunities in pharmaceuticals and medical technology. Although the stock is no longer a bargain—trading near all-time highs—it offers a compelling mix of capital preservation and growth. The combination of a 64-year dividend-growth streak, a low volatility profile, and a clear path to $100 billion in revenue makes J&J an attractive option for 2026. For investors tired of the unpredictability in the technology sector, Johnson & Johnson shows that, in the current market environment, boring can be both beautiful and profitable.
| 
